FDA Approved: DAPAGLIFLOZIN — Original Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves Lupin's original application for dapagliflozin tablets (generic), enabling market entry for the SGLT2 inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

ORIG AP for DAPAGLIFLOZIN (DAPAGLIFLOZIN)